Method for generating large quantities of mast cells for use in allergy drug research
An improved method for robust and rapid production of large quantities of homogeneous mast cells suitable for research, drug discovery and cell therapy to treat allergy, anaphylaxis and autoimmune disorders.
Drug discovery & screening (allergy, anaphylaxis and autoimmune disorders)
Early stage laboratory data / Proof of concept
UK priority application filed June 2016.
Licensing and/or collaborative research.
The global market for antihistamine and nasal allergy drugs is worth $7.6 billion, with 95 million seasonal allergy sufferers in US, EU and Japan. In the development of drugs against allergy, mast cells are a key target cell type and are used to see if a given compound prevents degranulation and release of histamine. Many companies want to access or provide mast cells commercially, but existing culture methods for generating mast cells are lengthy, inefficient and do not generate large numbers of pure mast cells.
Mast cells are key player in the inflammatory response and are implicated in allergy, anaphylaxis and autoimmune disorders. This technology is a useful improvement on current techniques, which makes use of a 3-step methodology: bioengineering of pluripotent stem cells with a key reporter construct; cellular expansion; and Fluorescence-activated cell sorting (FACS) enrichment, which generates a rapid, high yield of pure and highly proliferating immature and mature mast cells.
At present there is proof-of-concept data from mouse embryonic stem cells that have undergone a ~50-fold expansion within 21 days. All of the cells demonstrate the morphological characteristics of mast cells and expressed typical mast cell mediators following stimulation. Additionally, there is some preliminary data from human induced pluripotent stem cells which is currently in development.
- Potential for high cost savings
- Provides a robust functional cell population for studies
- Saves on user time, reduced culture times, less variability
- Applicable to embryonic and induced pluripotent stem cells
Please note, the featured image is purely illustrative.